Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

gwpharma

GW Pharmaceuticals says Phase III trials for Epidiolex to treat rare epilepsy in children shows positive results

June 27, 2016 Research and Development, Sales and Marketing Epidiolex, GW Pharmaceuticals, NDA, US FDA, drug trial, orphan drug

GW Pharmaceuticals (Nasdaq: GWPH) said late-stage trials for its Epidiolex (cannabidiol or CBD) to treat Lennox-Gastaut syndrome (LGS), a rare …
News

Boehringer Ingelheim says Phase III trials for its Ofev slowed progression of fatal lung disease

June 27, 2016 Research and Development, Sales and Marketing Boehringer Ingelheim, drug trial, idiopathic pulmonary fibrosis, research

German drugmaker Boehringer Ingelheim said late-stage trials for its Ofev (nintedanib) to treat a fatal lung condition slowed progression of …
News

Sanofi, Boehringer Ingelheim sign definitive agreements for swap

June 27, 2016 Research and Development, Sales and Marketing Boehringer Ingelheim, Financial, Sanofi, business swap, merger and acquisition

French drugmaker Sanofi (Euronext: SAN) and German pharma firm Boehringer Ingelheim have signed a definitive agreement for a business swap announced …
News
stocks1

Weekly Movers: Lpath, Paratek, Inovio…

June 27, 2016 Research and Development, Sales and Marketing

Shares in Lpath (Nasdaq: LPTN) jumped 55% after the company said it has secured a two-year $1.45 million grant by …
Feature
china-pharmaceutical-industry

Brexit may also create opportunities for UK’s pharmaceutical and medical device industries – report

June 27, 2016 Research and Development, Sales and Marketing

Even though UK’s exit from the European Union undoubtedly creates significant issues for the UK pharmaceutical and medical device industries …
News
astellas_imageuk

Astellas UK suspended from ABPI for “deception” and other cultural failings

June 24, 2016 Medical Communications, Research and Development, Sales and Marketing ABPI, Astellas, cultural failings

Astellas UK has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for a period …
News
brexit

“Immediate challenges” for UK pharma post-Brexit, says ABPI

June 24, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, brexit

The UK life sciences industry has expressed dismay at the result of the EU referendum, but has pledged to work …
News
allergan

FDA approves expanded label for Allergan’s Avycaz

June 24, 2016 Medical Communications, Research and Development, Sales and Marketing Allergan, Avycaz, FDA, expanded label

Allergan (NYSE: FDA) has announced that the US Food and Drug Administration (FDA) has approved its supplemental new drug application …
News
cancer

Genmab’s CLL drug gets negative opinion from EMA committee

June 24, 2016 Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer

Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …
News
sanofi_hq__boetie_hall

Sanofi to add future payments onto Medivation offer, according to reports

June 23, 2016 Research and Development, Sales and Marketing Medivation, Sanofi

Sanofi (NYSE: SNY) is considering adding future payments, tied to certain targets, to its proposed $9.3 billion takeover of US …
News
eu

EU referendum outcome will have major consequences for UK’s pharma sector – GlobalData

June 23, 2016 Medical Communications, Sales and Marketing EMA, GlobalData, Pharma sector, brexit, referendum

The outcome of today’s referendum on the UK’s continuing membership of the European Union (EU) will have major consequences for …
News
azhqlondonweb

AstraZeneca set to lose out on $80 million after US turns down flu vaccine

June 23, 2016 Sales and Marketing AstraZeneca, CDC, flu, flu vaccine

AstraZeneca has confirmed that its influenza vaccine, FluMist Quadrivalent, will not be used in the US during the 2016-17 flu …
News

Timely use of Novartis’ Entresto could prevent/delay over 28,000 US deaths a year – study

June 23, 2016 Research and Development, Sales and Marketing Entresto, JAMA Cardiology, Novartis, drug trial, research

A timely switch to Novartis’ (VTX: NOVN) heart failure drug Entresto (sacubitril/valsartan) in patients could prevent or delay more than …
News
stocks2

Immunomedics’ chief financial officer resigns, shares fall

June 22, 2016 Research and Development, Sales and Marketing Immunomedics, Shares, cfo, stock market

Shares in Immunomedics (Nasdaq: IMMU) fell as much as 11% after the company said its chief financial officer Peter Pfreundschuh …
News

Nice backs two cancer drugs from Novartis

June 22, 2016 Research and Development, Sales and Marketing AbbVie, Amgen, Humira, NICE, Novartis, Sanofi, lung cancer, skin cancer

The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer …
News
The Gateway to Local Adoption Series

Latest content

Jager-van Dijk is new Arletta Pharma Solutions CEO 

October 13, 2026

Tridem begins phase Ib trial of Parkinson’s disease vaccine

October 13, 2026

Bio-Techne opens GMP small-molecule manufacturing facility in Bristol

October 13, 2026

Trio become latest Symbiosis commercial additions

October 12, 2026

UK immunoglobulin supply faces growing pressure, report warns

October 12, 2026